ArciTect™ Human CRISPR Optimization Kit

Complete kit for optimization of genome editing in human cells

ArciTect™ Human CRISPR Optimization Kit

Complete kit for optimization of genome editing in human cells

From: 882 USD
Catalog #
100-0470_C
Complete kit for optimization of genome editing in human cells

What's Included

  • ArciTect™ Human CRISPR Optimization Kit, APC (Catalog #100-0470)
    • ArciTect™ Human B2M sgRNA, 2 nmol
    • ArciTect™ Cas9 Nuclease, 100 µg (Catalog #76002)
    • Anti-Human Beta-2 Microglobulin Antibody, Clone 35, APC, 25 tests
  • ArciTect™ Human CRISPR Optimization Kit, PE (Catalog #100-0471)
    • ArciTect™ Human B2M sgRNA, 2 nmol
    • ArciTect™ Cas9 Nuclease, 100 µg (Catalog #76002)
    • Anti-Human Beta-2 Microglobulin Antibody, Clone 35, PE, 25 tests
  • ArciTect™ Human CRISPR Optimization Kit, FITC (Catalog #100-0472)
    • ArciTect™ Human B2M sgRNA, 2 nmol
    • ArciTect™ Cas9 Nuclease, 100 µg (Catalog #76002)
    • Anti-Human Beta-2 Microglobulin Antibody, Clone 35, FITC, 25 tests
Products for Your Protocol
To see all required products for your protocol, please consult the Product Information Sheet.

Overview

The ArciTect™ Human CRISPR Optimization Kit is a flow cytometry-based kit designed to enable rapid optimization of genome editing in human cells. It can also be used as a positive control for experiments using the ArciTect™ CRISPR-Cas9 genome editing system in human cells. The kit comprises ArciTect™ Human B2M sgRNA, ArciTect™ Cas9 Nuclease, and a fluorophore-conjugated beta-2 microglobulin (B2M) antibody. ArciTect™ Cas9 Nuclease must first be complexed with ArciTect™ Human B2M sgRNA, followed by delivery into human cells and subsequent culture for 48 - 96 hours. Following culture, editing efficiency can be assessed quickly by collection and processing for flow cytometry using a fluorophore-conjugated B2M antibody.

This kit has been tested and validated for use with the ArciTect™ line of genome editing products. By targeting the B2M gene that encodes a ubiquitously expressed cell-surface protein, editing efficiency can be rapidly and quantitatively assessed using flow cytometry methods. This technique also enables additional evaluation of editing success such as viability monitoring and/or assessment of cell type-specific marker expression.
Cell Type
Hematopoietic Stem and Progenitor Cells, Intestinal Cells, Pluripotent Stem Cells, T Cells
Species
Human
Brand
ArciTect
Area of Interest
Immunology, Organoids, Stem Cell Biology

Scientific Resources

Product Documentation

Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

Document Type
Product Name
Catalog #
Lot #
Language
Catalog #
100-0470, 100-0471, 100-0472
Lot #
All
Language
English
Document Type
Safety Data Sheet 1
Catalog #
100-0470, 100-0471, 100-0472
Lot #
All
Language
English
Document Type
Safety Data Sheet 3
Catalog #
100-0470
Lot #
All
Language
English
Document Type
Safety Data Sheet 3
Catalog #
100-0470, 100-0471, 100-0472
Lot #
All
Language
English
Document Type
Safety Data Sheet 3
Catalog #
100-0471
Lot #
All
Language
English
Document Type
Safety Data Sheet 3
Catalog #
100-0472
Lot #
All
Language
English

Product Applications

Data and Publications

Figure 1. ArciTect™ Human CRISPR Optimization Kit Exhibits High Editing Efficiency in hPSCs, T Cells, and CD34+ Hematopoietic Stem and Progenitor Cells (HSPCs)

Cells were electroporated with RNP complexes containing sgRNA targeting B2M complexed with ArciTect™ Cas9 Nuclease protein. The cells were cultured for 72 hours following electroporation and editing efficiency was monitored by flow cytometry to detect loss of B2M expression; n = 3 biological replicates (WLS-1C iPSCs/hPSCs) or n = 3 donors (T cells and CD34+ HSPCs). No EP: non-electroporated controls.

Figure 2. Anti-Human Beta-2-Microglobulin, Clone #35 Conjugates Exhibit Equivalent Performance Across Samples to Monitor B2M Knockout Efficiency Using the ArciTect™ Human CRISPR Optimization Kit

CD34+ HSPCs isolated from two independent donors were electroporated with RNP complexes containing sgRNA targeting B2M complexed with ArciTect™ Cas9 Nuclease protein. The cells were cultured for 96 hours following electroporation and editing efficiency was monitored by flow cytometry to detect loss of B2M expression using anti-human beta-2-microglobulin, clone #35, (A, B) APC-conjugated, (C, D) FITC-conjugated, and (E, F) PE-conjugated. The histograms were derived from gated events of viable (7-AAD-negative) cells. Orange histograms: RNP-electroporated samples; grey histograms: non-electroporated control samples.

Contact STEMCELL Technologies

Our Customer Service, Sales, and Product and Scientific Support departments in North America are available between 6 am and 5 pm Pacific Time (9 am and 8 pm Eastern Time). One of our representatives will be happy to help you by telephone or email. Please complete the form to contact us by email. A representative will get back to you shortly.
  •  

StemCell Technologies Inc. and affiliates ("STEMCELL Technologies") does not share your email address with third parties. StemCell Technologies Inc. will use your email address to confirm your identity and send you newsletters, transaction-related emails, promotional and customer service emails in accordance with our privacy policy. You can change your email preferences at any time.